Andersons pediatric cardiology 2349
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (76.84 KB, 3 trang )
exercisetestingand,394,394b,395f–396f
inFontanpathway,1274,1274t,1285–1288
inmyocarditis,1174,1175f
duringpregnancy,1441–1442
forpulmonaryhypertension,1387
inpulmonarystenosis,781–782
insuddencardiacdeath,1537–1538
Electroencephalography,inFontanpathway,1275,1288
continuous,ofcentralnervoussystem,1291
Electronichealthrecord,structureof,1492,1493f
Electrophysiology,335–378
intracardiacrecordingsandprogrammedstimulation,359–364
study,358
invasive,358–359
transesophageal,358
oftelemedicineinpediatriccardiology,1556–1557
testing,357–364
Ellis-vanCreveldsyndrome,1414–1415,1414f,1414t
Embolism,paradoxical,interatrialcommunicationand,514
Emergencycontraceptionwithcongenitalheartdisease,1442
Emery-Dreifussmusculardystrophy,cardiacinvolvementin,1104–1105
Enalapril
asantihypertensives,1437–1438
forhypertension,1140t
Enantiomerism,442–443,442f
biological,442–443,442f
Endocardialfibrosis,1111b
Endocarditis
bicuspidaorticvalveand,831
prophylaxisfor,801
Endoderm,33,34f
Endomyocardialbiopsy
inmyocarditis,1175–1176,1177f
three-dimensionalechocardiographyand,316
Endomyocardialfibrosis,restrictivecardiomyopathyand,1159
Endoplasmicreticulum(ER)stressresponse,69
Endothelialcells,inmyocardialdevelopment,65–66
Endothelialdysfunction,1366–1367
congenitalheartdiseaseand,1374
Endothelialfunction,1356
invivo,assessmentof,1367–1369
circulatingbiomarkersfor,1368–1369
inconduitartery,1367–1368,1368f
incoronarycirculation,1367
inforearmresistancevessels,1367
inmicrovasculature,1368,1369f
Endothelinreceptorantagonists,forpulmonaryhypertension,1390
Endothelium,1355
Enhancers,cardiacdevelopmentand,51
Enteralnutrition,1499
Enteropathy,protein-losing,inFontan-associatedliverdisease,1333–1334
Enteroviruses,inviralmyocarditis,1173
Environmentalfactors
incongenitalheartdisease,49–50
prevalenceofcongenitalheartdiseaseand,176–177,177t
Environments,resourcelimited,deliveringpediatricheartcarein,1528–1532
continuingmedicaleducationandtraininginitiativesin,1532
establishingandsustainingpediatricheartprogramsin,1530–1531,1530f,1531t
generalprinciplesof,1526f,1528–1530,1529t
qualityimprovementinitiativesforprogramsin,1532
trainingprogramsin,1531–1532
intouniversalhealthcaremodels,integrating,1531
Eosinophiliccardiomyopathy,1159
Epinephrine
foracutecirculatoryfailure,1184t
forhypotensionandcirculatorycollapse,inprematurity,202–204
Epistaxis,inrheumaticfever,1011
Ergometers,exercisetesting,387–388,387t
cycle,388,389f
treadmill,387,388f
Error,typesIandII,413
Erythemamarginatum,inrheumaticfever,1010–1011,1011f
Erythromycinestolate,forrheumaticfeverprevention,1016t
Esmolol,forsystemichypertension,inprematureinfants,208f
Esophagealcompression
managementofanomaliescausing,893–898
vascularringsand,888
Essentialfattyacids,nutritionand,1501–1502
Ethicalissues,inpediatriccardiologyandcongenialheartdisease
benefitsofgenetictesting,1467
bioethicsconsultationandpediatricpalliativecare,1472
incardiactransplantation,1475–1477
counseling,1468–1469
culturalandmoraldiversity,1471,1471t
fetalcenters,1468
fetalinterestsof,1468
fetalinterventionsof,1467–1469
ofgenetictestinganduniquefeaturesofcongenitalheartdisease,1466–1467
inglobaloutreach,1478–1479
withhypoplasticleftheartsyndrome,1465
innovativepractice,1468
maternalrights,1468
moraldistressandmoralresilience,1474–1475,1475b
inpediatriccardiologyandcongenialheartdisease,1465–1479
